Amplia Therapeutics' Patent Grant Announcement

Amplia Therapeutics Limited (ASX: $ATX) has announced the granting of a key patent in Europe and Japan for its best-in-class FAK inhibitor narmafotinib. The patent extends protection for narmafotinib to at least 2040 in these markets, providing a stable and manufacturable form of the drug that enhances drug levels upon dosing. This specific form of the drug is currently being developed clinically by the Company, including in the Phase 2a ACCENT trial in advanced pancreatic cancer.

Executive Commentary on Patent Grant

The granting of this patent by two of the world's most respected patent offices bodes well for granting of the patent in other jurisdictions, including the US and Australia. Importantly from a commercial perspective, this patent extends protection for narmafotinib out to at least 2040. - Dr Chris Burns, CEO and Managing Director of Amplia Therapeutics

Summary of Amplia Therapeutics' Patent Grant

Amplia Therapeutics Limited (ASX: $ATX) has successfully secured a key patent for its best-in-class FAK inhibitor narmafotinib in Europe and Japan, extending patent protection to at least 2040 in these major markets. The specific chemical form of narmafotinib described in the patent provides improved drug levels upon dosing and is currently being developed clinically by the Company. The CEO and Managing Director, Dr Chris Burns, highlighted the significance of this patent grant, indicating its positive implications for potential grants in other jurisdictions. Amplia Therapeutics continues to advance its pipeline of FAK inhibitors for cancer and fibrosis, with a particular focus on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF). The Company's ongoing Phase 2a ACCENT trial in advanced pancreatic cancer aims to assess the safety, tolerability, and efficacy of narmafotinib in combination with chemotherapies gemcitabine and Abraxane. Amplia Therapeutics remains committed to its corporate strategy of developing innovative treatments for challenging diseases and looks forward to further progress in its clinical development and patent protection efforts.